Dr. Adam M. Forman
Claim this profileAscension Providence Hospitals - Southfield
About Adam M. Forman
Education:
- Graduated with a Doctor of Medicine (MD) from Wayne State University School of Medicine.
- Completed Residency in Internal Medicine at St. John Hospital and Medical Center.
- Undertook a Fellowship in Gastroenterology at Henry Ford Hospital.
Experience:
- Currently practices as a gastroenterologist at Ascension Providence Hospitals - Southfield.
Area of expertise
Lung Cancer
Adam M. Forman has run 10 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Adam M. Forman has run 8 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Ascension Providence Hospitals - Southfield
Ascension Providence Hospitals - Novi
Clinical Trials Adam M. Forman is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting
2 awards
Phase 3
40 criteria
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting
1 award
Phase 2 & 3
20 criteria
More about Adam M. Forman
Clinical Trial Related
6 years of experience running clinical trials · Led 25 trials as a Principal Investigator · 11 Active Clinical Trials
Treatments Adam M. Forman has experience with
- Atezolizumab
- Carboplatin
- Pembrolizumab
- Nivolumab
- Lenalidomide
- Durvalumab
Breakdown of trials Adam M. Forman has run
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Adam M. Forman specialize in?
Adam M. Forman focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Adam M. Forman currently recruiting for clinical trials?
Yes, Adam M. Forman is currently recruiting for 11 clinical trials in Southfield Michigan. If you're interested in participating, you should apply.
Are there any treatments that Adam M. Forman has studied deeply?
Yes, Adam M. Forman has studied treatments such as Atezolizumab, Carboplatin, Pembrolizumab.
What is the best way to schedule an appointment with Adam M. Forman?
Apply for one of the trials that Adam M. Forman is conducting.
What is the office address of Adam M. Forman?
The office of Adam M. Forman is located at: Ascension Providence Hospitals - Southfield, Southfield, Michigan 48075 United States. This is the address for their practice at the Ascension Providence Hospitals - Southfield.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.